Stablepoint Partners LLC Sells 4,840 Shares of GSK plc (NYSE:GSK)

Stablepoint Partners LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 4.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 99,564 shares of the pharmaceutical company’s stock after selling 4,840 shares during the period. Stablepoint Partners LLC’s holdings in GSK were worth $3,367,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Eastern Bank bought a new position in GSK during the third quarter worth about $26,000. ST Germain D J Co. Inc. raised its holdings in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. lifted its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Concord Wealth Partners boosted its stake in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new stake in GSK in the third quarter valued at $42,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

Shares of NYSE:GSK opened at $34.29 on Friday. The stock has a market capitalization of $71.06 billion, a P/E ratio of 22.26, a P/E/G ratio of 1.31 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The business has a 50-day moving average price of $33.91 and a two-hundred day moving average price of $37.81.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.58%. GSK’s dividend payout ratio (DPR) is presently 96.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.